BACKGROUND: HIV is associated with elevated markers of vascular remodeling that may contribute to arterial fibrosis and stiffening and changes in pulse pressure (PP). These changes may, in turn, deleteriously affect autoregulation of cerebral blood flow and neurocognitive function. METHODS: To evaluate these mechanisms, we studied markers of vascular remodeling, PP, and neurocognitive function among older (≥50 years of age) HIV-infected (HIV+, n = 72) and HIV-seronegative (HIV-, n = 36) adults. Participants completed standardized neurobehavioral and neuromedical assessments. Neurocognitive functioning was evaluated using a well-validated comprehensive battery. Three plasma biomarkers of vascular remodeling (ie, angiopoietin 2, Tie-2, and vascular endothelial growth factor, VEGF) were collected. RESULTS: HIV+ and HIV- participants had similar levels of plasma angiopoietin 2 (P = 0.48), Tie-2 (P = 0.27), VEGF (P = 0.18), and PP (P = 0.98). In a multivariable regression model, HIV interacted with Tie-2 (β = 0.41, P < 0.01) and VEGF (β = -0.43, P = 0.01) on neurocognitive function, such that lower Tie-2 and higher VEGF values were associated with worse neurocognitive function for HIV+ participants. Greater Tie-2 values were associated with increased PP (r = 0.31, P < 0.01). In turn, PP demonstrated a quadratic association with neurocognitive function (β = -0.33, P = 0.01), such that lower and higher, relative to mean sample, PP values were associated with worse neurocognitive function. CONCLUSIONS: These findings indicate that vascular remodeling and altered cerebral blood flow autoregulation contribute to neurocognitive function. Furthermore, HIV moderates the association between vascular remodeling and neurocognitive function but not the association between PP and neurocognitive function.
BACKGROUND: HIV is associated with elevated markers of vascular remodeling that may contribute to arterial fibrosis and stiffening and changes in pulse pressure (PP). These changes may, in turn, deleteriously affect autoregulation of cerebral blood flow and neurocognitive function. METHODS: To evaluate these mechanisms, we studied markers of vascular remodeling, PP, and neurocognitive function among older (≥50 years of age) HIV-infected (HIV+, n = 72) and HIV-seronegative (HIV-, n = 36) adults. Participants completed standardized neurobehavioral and neuromedical assessments. Neurocognitive functioning was evaluated using a well-validated comprehensive battery. Three plasma biomarkers of vascular remodeling (ie, angiopoietin 2, Tie-2, and vascular endothelial growth factor, VEGF) were collected. RESULTS: HIV+ and HIV- participants had similar levels of plasma angiopoietin 2 (P = 0.48), Tie-2 (P = 0.27), VEGF (P = 0.18), and PP (P = 0.98). In a multivariable regression model, HIV interacted with Tie-2 (β = 0.41, P < 0.01) and VEGF (β = -0.43, P = 0.01) on neurocognitive function, such that lower Tie-2 and higher VEGF values were associated with worse neurocognitive function for HIV+ participants. Greater Tie-2 values were associated with increased PP (r = 0.31, P < 0.01). In turn, PP demonstrated a quadratic association with neurocognitive function (β = -0.33, P = 0.01), such that lower and higher, relative to mean sample, PP values were associated with worse neurocognitive function. CONCLUSIONS: These findings indicate that vascular remodeling and altered cerebral blood flow autoregulation contribute to neurocognitive function. Furthermore, HIV moderates the association between vascular remodeling and neurocognitive function but not the association between PP and neurocognitive function.
Authors: M Cherner; P Suarez; D Lazzaretto; L Artiola I Fortuny; Monica Rivera Mindt; S Dawes; Thomas Marcotte; I Grant; R Heaton Journal: Arch Clin Neuropsychol Date: 2007-02-12 Impact factor: 2.813
Authors: Michael P Dubé; Steven E Lipshultz; Carl J Fichtenbaum; Richard Greenberg; Alison D Schecter; Stacy D Fisher Journal: Circulation Date: 2008-06-19 Impact factor: 29.690
Authors: Zheng Gang Zhang; Li Zhang; Wayne Tsang; Hamid Soltanian-Zadeh; Daniel Morris; Ruilan Zhang; Anton Goussev; Cecylia Powers; Thomas Yeich; Michael Chopp Journal: J Cereb Blood Flow Metab Date: 2002-04 Impact factor: 6.200
Authors: Jose Gutierrez; Lawrence Honig; Mitchell S V Elkind; Jay P Mohr; James Goldman; Andrew J Dwork; Susan Morgello; Randolph S Marshall Journal: Neurology Date: 2016-03-16 Impact factor: 9.910
Authors: M E Marketou; J E Kontaraki; N A Tsakountakis; E A Zacharis; G E Kochiadakis; D A Arfanakis; G Chlouverakis; P E Vardas Journal: J Hum Hypertens Date: 2010-01-14 Impact factor: 3.012
Authors: Shari R Waldstein; S Carrington Rice; Julian F Thayer; Samer S Najjar; Angelo Scuteri; Alan B Zonderman Journal: Hypertension Date: 2007-11-19 Impact factor: 10.190
Authors: Jeroen P H van Wijk; Eelco J P de Koning; Manuel Castro Cabezas; Jorge Joven; Jos op't Roodt; Ton J Rabelink; Andy M Hoepelman Journal: J Am Coll Cardiol Date: 2006-02-23 Impact factor: 24.094
Authors: Jessica L Montoya; Laura M Campbell; Emily W Paolillo; Ronald J Ellis; Scott L Letendre; Dilip V Jeste; David J Moore Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731
Authors: Yang Qu; Andrea Weinstein; Zheng Wang; Yu Cheng; Lawrence Kingsley; Andrew Levine; Eileen Martin; Cynthia Munro; Ann B Ragin; Leah H Rubin; Ned W Sacktor; Eric C Seaberg; James T Becker Journal: AIDS Date: 2022-01-01 Impact factor: 4.177
Authors: Bin Tang; A C Collier; S Morgello; D Cookson; N Sacktor; Ronald J Ellis; Christina M Marra; David B Clifford; Benjamin B Gelman; Jessica Robinson-Papp; J Allen McCutchan; Scott Letendre; Robert K Heaton; Igor Grant Journal: Brain Behav Immun Health Date: 2022-03-10
Authors: F A Tobolowsky; N Wada; O Martinez-Maza; L Magpantay; S L Koletar; F J Palella; T T Brown; J E Lake Journal: PLoS One Date: 2018-01-30 Impact factor: 3.240